Giannopoulos K, Mertens D, Buehler A, Barth TFE, Idler I, Möller P, Kröber A, Greiner J, Chocholska S, Dmoszynska A, Rolinski J, Döhner H, Stilgenbauer S, Schmitt M. The candidate immunotherapeutical target receptor for hyaluronic acid mediated motility (RHAMM) is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 23:519-527, 2009. (IF: 8,634) |
Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Gotz M, Hey-duk M, Ritter G, Speiser DE, Gnjatic S, Guillaume P, Ringhoffer M, Schlenk RF, Liebisch P, Bunjes D, Shiku H, Döhner H, Greiner J. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits im-munological and clinical responses. Blood 111:1357-1365, 2008. (IF: 10,432) |
Hus I*, Schmitt M*, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszyńska A, Roliński J. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells towards an anti-leukemia response. Leukemia 22:1007-1017, 2008. (*both authors contributed equally) (IF: 8,634) |
Greiner J*, Schmitt M*, Li L, Giannopoulos K, Bösch K, Döhner K, Schlenk RF, Pollack JR, Döhner H, Bullinger L. Expression of tumor-associated antigens (TAAs) in acute mye-loid leukemia (AML): implications for specific immunotherapeutic approaches. Blood 108:4109-4117, 2006. (*both authors contributed equally) (IF: 10,432) |
Greiner J, Li L, Ringhoffer M, Barth T, Wiesneth M, Döhner H, Schmitt M. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood 106:938-945, 2005. (IF: 10,432) |